NEW YORK, March 15 – Arena Pharmaceuticals has enlisted the help of Celera’s databases and bioinformatics tools to identify G protein-coupled receptors (GPCRs), the companies said Thursday. 

Financial terms of Arena's multi-year subscription to the Celera Discovery System were not disclosed, but Celera has previously said that non-academic subcribers pay $5 million to $15 million a year. After signing Arena, Celera now has eight known commercial subscribers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.